Tag Archives: transcatheter aortic valve replacement

pacemaker marcapasos definitivo

SAFE-TAVI Study: Safety and Efficacy of the Pressure Sensor and Pacing Guidewire

SAFE-TAVI Study: Safety and Efficacy of the Pressure Sensor and Pacing Guidewire

Currently, we observe an increase in the number of transcatheter aortic valve replacement (TAVR) procedures due to its expansion toward a younger population with lower risk. For this reason, it is crucial to maintain continuous technological innovation to minimize post-procedural complications. The FDA has approved the SavyWire, a preformed 0.035-caliber guidewire that offers three essential

TCT 2023 | ALIGN AR trial

TCT 2023 | EVOLUT Low Risk: 4-Year Follow-up

In recent years, there has been a steady increase in the use of transcatheter aortic valve replacement (TAVR) in younger patients, with an average age of 74 years, as observed in US medical records. This trend goes alongside encouraging durability results, as demonstrated in the 10-year NOTION study, where structural valve degeneration (SVD) with first-generation

TCT 2023 | ALIGN AR trial

TCT 2023 | The WATCH-TAVR Study

In the TVT registry, around 40% of the patients eligible for transcatheter aortic valve replacement (TAVR) had atrial fibrillation, and there were high levels of adverse events after starting anticoagulant treatment, especially with oral anticoagulants (VKAs), primarily due to bleeding. The purpose of this study was to assess the feasibility, safety, and efficacy of combined

Sedación consciente vs anestesia general en el TAVI

Cause of Cardiac Death after TAVR at Present

Cardiac failure (CF) and sudden cardiac death (SCD) stand out as two of the main causes of death in patients with aortic stenosis. Although transcatheter aortic valve intervention has shown higher survival, these two continue to be the main conditions leading to patient death at followup.  In its early days, TAVR also showed benefits, but

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

TAVR Durability at 5 Years in Intermediate Risk Patients

TAVR has been shown beneficial in patients across the risk spectrum. The PARTNER 2 SAPIEN 3 (P2S3i) study on intermediate risk patients was the first to show TAVR superiority vs SAVR when using the transfemoral approach.  SAVR durability has been shown in different analysis but, except for a few reports, TAVR durability at long term

El estudio CULPRIT-SHOCK finalmente se publica en el NEJM y llega para cambiar las guías

Aortic Stenosis and Cardiogenic Shock: Is TAVR an Option?

Cardiogenic shock (CS) in a setting of aortic stenosis is associated with high mortality rates. In consequence, surgery is generally not a possibility for this patient group, and they usually undergo aortic valvuloplasty, resulting in a mortality rate of 33%-50% at 30 days, 70% at one year, and 90% at two years. While transcatheter aortic

TAVI bajo riesgo

Evolute Low Risk at 3 Years: Promising Outcomes

Transcatheter aortic valve replacement has shown important benefits but one of its biggest challenges is showing its safety and efficacy at followup in low risk patients. At present we have 2-year data from the Evolute Low Risk, but the we lack information at longer followup.  The study looked at 3-year followup of the Evolute Low

Sobrevida en pacientes con insuficiencia tricuspídea según variables clínicas y ecocardiográficas (Clusters)

High Implantation of Self-Expanding Valves in the Aortic Position or Cusp Overlapping: Should It Be the New “Gold Standard”?

Transcatheter aortic valve replacement (TAVR) has been proving its benefit in different scenarios for two decades now. However, in the field of self-expanding valves, one challenge has always been its high rate of pacemaker implantation compared with balloon-expandable devices and valvular replacement surgery. For this reason, the high implantation or Cusp Overlapping strategy was developed.

By pass y actividad de la enfermedad en la arteria coronaria nativa

Clinical Impact of Coronary Artery Disease on Results After TAVR

Coronary artery disease (CAD) coexists with aortic stenosis in about half the patients who suffer the latter. These patients receiving antiplatelet therapy are at a higher risk of periprocedural bleeding—one of the most frequent complications in patients who undergo transcatheter aortic valve replacement (TAVR). One way of limiting the risk for bleeding is choosing the

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVI

Percutaneous Access Closure in TAVR: Are Devices Similar?

One of the challenges that transcatheter aortic valve replacement (TAVR) continues to face is percutaneous access closure with percutaneous closure systems (PCS). However, several systems have been developed, either by plug—such as the MANTA system—or by suture (SU)—such as the ProStar and ProGlide systems. Both of these have been tested in different analyses, but to

Top